Top

Published in:

01-01-2013 | Laboratory Investigation

The role of LAT1 in ¹⁸F-DOPA uptake in malignant gliomas

Authors: Ryan S. Youland, Gaspar J. Kitange, Timothy E. Peterson, Deanna H. Pafundi, Judi A. Ramiscal, Jenny L. Pokorny, Caterina Giannini, Nadia N. Laack, Ian F. Parney, Val J. Lowe, Debra H. Brinkmann, Jann N. Sarkaria

Published in: Journal of Neuro-Oncology | Issue 1/2013

Abstract

Positron emission tomography (PET) imaging with the amino acid tracer 6-¹⁸F-fluoro-l-3,4-dihydroxy-phenylalanine (¹⁸F-DOPA) may provide better spatial and functional information in human gliomas than CT or MRI alone. The l-type amino acid transporter 1 (LAT1) is responsible for membrane transport of large neutral amino acids in normal cells. This study assessed the relationship between LAT1 expression and ¹⁸F-DOPA uptake in human astrocytomas. Endogenous LAT1 expression was measured in established glioblastoma (GBM) cell lines and primary GBM xenografts using Western blotting and quantitative reverse transcription polymerase chain reaction (qRT-PCR). Uptake of ¹⁸F-DOPA was approximated in vitro using ³H-l-DOPA as an analog. Uptake of ³H-l-DOPA was assessed in cells expressing LAT1 shRNA or LAT1 siRNA and compared to non-targeted (NT) control shRNA or siRNA sequences, respectively. To demonstrate the clinical relevance of these findings, LAT1 immunofluorescence staining was compared with corresponding regions of ¹⁸F-DOPA PET uptake in patients with newly diagnosed astrocytomas. LAT1 mRNA and protein expression varies in GBM, and the extent of ³H-l-DOPA uptake was positively correlated with endogenous LAT1 expression. Stable shRNA-mediated LAT1 knockdown in T98 and GBM28 reduced ³H-l-DOPA uptake relative to NT shRNA by 57 (P < 0.0001) and 52 % (P < 0.001), respectively. Transient siRNA-mediated LAT1 knockdown in T98 reduced ³H-l-DOPA uptake relative to NT siRNA up to 68 % (P < 0.01). In clinical samples, LAT1 expression positively correlated with ¹⁸F-DOPA PET uptake (P = 0.04). Expression of LAT1 is strongly associated with ³H-l-DOPA uptake in vitro and ¹⁸F-DOPA uptake in patient biopsy samples. These results define LAT1 as a key determinant of ¹⁸F-DOPA accumulation in GBM.

Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W (2009) ¹⁸F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol 71:242–248. doi:10.1016/j.ejrad.2008.04.018 PubMedCrossRef

Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904–911PubMed

Tripathi M, Sharma R, D’Souza M, Jaimini A, Panwar P, Varshney R, Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, Mondal A (2009) Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 34:878–883. doi:10.1097/RLU.0b013e3181becfe0 PubMedCrossRef

Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J (2012) Impact of 3,4-dihydroxy-6-18F-fluoro-l-phenylalanine PET/CT on managing patients with brain tumors: the referring physician’s perspective. J Nucl Med 53:393–398. doi:10.2967/jnumed.111.095711 PubMedCrossRef

Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC (2007) 18F-FDOPA kinetics in brain tumors. J Nucl Med 48:1651–1661. doi:10.2967/jnumed.106.039321 PubMedCrossRef

Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, Shimohama S (2000) The 4F2hc/LAT1 complex transports l-DOPA across the blood-brain barrier. Brain Res 879:115–121PubMedCrossRef

del Amo EM, Urtti A, Yliperttula M (2008) Pharmacokinetic role of l-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35:161–174. doi:10.1016/j.ejps.2008.06.015 PubMedCrossRef

Pinho MJ, Serrao MP, Gomes P, Hopfer U, Jose PA, Soares-da-Silva P (2004) Over-expression of renal LAT1 and LAT2 and enhanced l-DOPA uptake in SHR immortalized renal proximal tubular cells. Kidney Int 66:216–226. doi:10.1111/j.1523-1755.2004.00722.x PubMedCrossRef

Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273:23629–23632PubMedCrossRef

10.

Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T (2010) Correlation of l-methyl-11C-methionine (MET) uptake with l-type amino acid transporter 1 in human gliomas. J Neurooncol 99:217–225. doi:10.1007/s11060-010-0117-9 PubMedCrossRef

11.

Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y, Nagane M (2008) Enhanced tumor growth elicited by l-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery 62:493–503. doi:10.1227/01.neu.0000316018.51292.19 discussion 503–494PubMedCrossRef

12.

Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H (2006) l-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119:484–492. doi:10.1002/ijc.21866 PubMedCrossRef

13.

Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164–176. doi:10.1215/S1152851704000821 PubMedCrossRef

14.

Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11:281–291. doi:10.1215/15228517-2008-090 PubMedCrossRef

15.

Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23:1409–1415PubMedCrossRef

16.

Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, Tamiya T (2008) 11C-methionine (MET) and ¹⁸F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35:2009–2017. doi:10.1007/s00259-008-0847-5 PubMedCrossRef

17.

Pafundi DH, Brinkmann DH, Parney IF, Giannini C, Laack NN, Kemp B, Lowe V, Sarkaria JN, Yan ES (2011) Biopsy validation of (18)F-FDOPA-PET uptake and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: preliminary results of a prospective pilot study. Int J Radiat Oncol 81:S182–S182CrossRef

18.

Asano S, Kameyama M, Oura A, Morisato A, Sakai H, Tabuchi Y, Chairoungdua A, Endou H, Kanai Y (2007) l-type amino acid transporter-1 expressed in human astrocytomas, U343MGa. Biol Pharm Bull 30:415–422PubMedCrossRef

19.

Soares-da-Silva P, Serrao MP (2004) High- and low-affinity transport of l-leucine and l-DOPA by the hetero amino acid exchangers LAT1 and LAT2 in LLC-PK1 renal cells. Am J Physiol Renal Physiol 287:F252–F261. doi:10.1152/ajprenal.00030.2004 PubMedCrossRef

20.

Kuhne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, Brockmoller J (2009) Influx and efflux transport as determinants of melphalan cytotoxicity: resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol 78:45–53. doi:10.1016/j.bcp.2009.03.026 PubMedCrossRef

21.

Kim CH, Park KJ, Park JR, Kanai Y, Endou H, Park JC, Kim do K (2006) The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells. Anticancer Res 26:2943–2948PubMed

22.

Kumakura Y, Vernaleken I, Grunder G, Bartenstein P, Gjedde A, Cumming P (2005) PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity. J Cereb Blood Flow Metab 25:807–819. doi:10.1038/sj.jcbfm.9600079 PubMedCrossRef

23.

Bauer R, Brust P, Walter B, Vorwieger G, Bergmann R, Fuchtner F, Steinbach J, el-Hallag E, Fritz A, Johannsen B, Zwiener U (2000) Relation between brain tissue pO2 and dopamine synthesis of basal ganglia—a 18FDOPA-PET study in newborn piglets. J Perinat Med 28:54–60. doi:10.1515/JPM.2000.008 PubMedCrossRef

24.

Beuthien-Baumann B, Bredow J, Burchert W, Fuchtner F, Bergmann R, Alheit HD, Reiss G, Hliscs R, Steinmeier R, Franke WG, Johannsen B, Kotzerke J (2003) 3-O-methyl-6-[18F]fluoro-l-DOPA and its evaluation in brain tumour imaging. Eur J Nucl Med Mol Imaging 30:1004–1008. doi:10.1007/s00259-003-1205-2 PubMedCrossRef

25.

Lennernas H, Nilsson D, Aquilonius SM, Ahrenstedt O, Knutson L, Paalzow LK (1993) The effect of l-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol 35:243–250PubMedCrossRef

26.

Morimoto E, Kanai Y, Kim do K, Chairoungdua A, Choi HW, Wempe MF, Anzai N, Endou H (2008) Establishment and characterization of mammalian cell lines stably expressing human l-type amino acid transporters. J Pharmacol Sci 108:505–516PubMedCrossRef

27.

Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, Anzai N, Suzuki Y, Endou H, Okayasu I (2011) High expression of l-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int 61:281–289. doi:10.1111/j.1440-1827.2011.02650.x PubMedCrossRef

28.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M (2009) l-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. J Surg Oncol 99:433–438. doi:10.1002/jso.21277 PubMedCrossRef

29.

Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Oyama T, Mori M, Endo K (2010) Comparison of l-type amino acid transporter 1 expression and l-[3-18F]-alpha-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol 37:911–916. doi:10.1016/j.nucmedbio.2010.06.004 PubMedCrossRef

30.

Kobayashi H, Ishii Y, Takayama T (2005) Expression of l-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 90:233–238. doi:10.1002/jso.20257 PubMedCrossRef

31.

Nakanishi K, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, Mukai M, Ikeda E, Ozeki Y, Aida S, Kawai T (2006) LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch 448:142–150. doi:10.1007/s00428-005-0063-7 PubMedCrossRef

32.

Nakanishi K, Ogata S, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, Aida S, Kasamatsu H, Kawai T (2007) Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 451:681–690. doi:10.1007/s00428-007-0457-9 PubMedCrossRef

33.

Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, Ueno A, Kanai Y, Endou H, Okayasu I (2009) l-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 59:7–18. doi:10.1111/j.1440-1827.2008.02319.x PubMedCrossRef

34.

Ebara T, Kaira K, Saito J, Shioya M, Asao T, Takahashi T, Sakurai H, Kanai Y, Kuwano H, Nakano T (2010) l-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer. Anticancer Res 30:4223–4227PubMed

35.

Boado RJ, Li JY, Tsukamoto H, Pardridge WM (2003) Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells. J Neurochem 85:1037–1042PubMedCrossRef

36.

Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N (2011) LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res 3:468–478PubMed

37.

Cohen A, Hall MN (2009) An amino acid shuffle activates mTORC1. Cell 136:399–400. doi:10.1016/j.cell.2009.01.021 PubMedCrossRef

38.

Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, Rasko JE, Holst J (2011) Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res 71:7525–7536. doi:10.1158/0008-5472.CAN-11-1821 PubMedCrossRef

39.

Roos S, Kanai Y, Prasad PD, Powell TL, Jansson T (2009) Regulation of placental amino acid transporter activity by mammalian target of rapamycin. Am J Physiol Cell Physiol 296:C142–C150. doi:10.1152/ajpcell.00330.2008 PubMedCrossRef

40.

Kim CS, Cho SH, Chun HS, Lee SY, Endou H, Kanai Y, Kim do K (2008) BCH, an inhibitor of system l amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull 31:1096–1100PubMedCrossRef

41.

Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Nagamori S, Promchan K, Nakajima T, Yamamoto N, Mori M, Kanai Y (2010) Inhibition of l-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res 30:4819–4828PubMed

42.

Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y, Endou H (2010) l-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 101:173–179. doi:10.1111/j.1349-7006.2009.01386.x PubMedCrossRef

Title: The role of LAT1 in 18F-DOPA uptake in malignant gliomas
Authors: Ryan S. Youland
Gaspar J. Kitange
Timothy E. Peterson
Deanna H. Pafundi
Judi A. Ramiscal
Jenny L. Pokorny
Caterina Giannini
Nadia N. Laack
Ian F. Parney
Val J. Lowe
Debra H. Brinkmann
Jann N. Sarkaria
Publication date: 01-01-2013
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2013
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-012-0986-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The role of LAT1 in ¹⁸F-DOPA uptake in malignant gliomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806)

EGFR mutation status in brain metastases of non-small cell lung carcinoma

Acknowledgement of reviewers 2011

MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas

Anaplastic PXA in adults: case series with clinicopathologic and molecular features

Erratum to: The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas